$TCAN Appoints Haywood Securities as Lead Agent on $10M Brokered Private Placement

$LXRP Enters New Licensing Agreement, Strengthens Business Model

• Lexaria continues to create a strong, revenue-generating business model to support its growing patent portfolio
• The company out-licenses disruptive delivery technology, giving licensees access to existing patents
• Lexaria entered into a new beverage license agreement with a California-based cannabis firm
• The company recently announced four new appointments to its scientific advisory board

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a drug-delivery platform innovator with existing cannabinoid licensing agreements in Canada and the United States, as well as internationally. By out-licensing disruptive delivery technology DehydraTECH, the company has created a strong, revenue-generating business model and a growing patent portfolio.

At the end of 2018, LXRP held 10 granted patents, with 53 patent applications filed and pending in more than 40 countries around the world. The company is unique in that it is the only…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$CNPOF $RIV $RIV.V Congratulates $TRSSF on Receiving EU GMP Cert.

TORONTO, May 3, 2019 – Canopy Rivers Inc. (“Canopy Rivers” or the “Company“) (TSXV: RIV) (OTC: CNPOF) congratulates its portfolio company TerrAscend Corp. (“TerrAscend“) (CSE: TER) (OTCQX: TRSSF) on its announcement yesterday that its facility in Mississauga, Ontario, Canada has been issued a Good Manufacturing Practice (“GMP“) certificate in accordance with the rules governing medicinal products in the European Union (“EU“). TerrAscend also entered into a comprehensive sales and distribution agreement with iuvo Therapeutics GmbH (“iuvo“), a German pharmaceutical wholesaler.

Only medical cannabis from EU GMP certified facilities, or the equivalent, may be sold in the EU. The regulatory approach has been led by several of the larger EU countries and as such, pharmaceutical grade controls in production were an established requirement from the onset of medical cannabis legalization. Through iuvo, management at TerrAscend expects to begin shipping pharmaceutical-grade cannabis products into Germany.

“We applaud TerrAscend for achieving one of the highest and most rigorous levels of quality certification in the world,” said Narbe Alexandrian, President of Canopy Rivers. “TerrAscend is now one of select Canadian licensed producers that have been issued EU GMP certificates, and with its new distribution arrangement with iuvo, becomes the first and only cannabis operator with sales in US, Canada, and Europe.”

In October 2018, to accommodate TerrAscend’s strategic pursuits internationally, including select opportunities in the United States, Canopy Rivers agreed to restructure its investment and waive certain restrictive covenants that were granted by TerrAscend, in connection with its original investment.

About Canopy Rivers:

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers works collaboratively with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) to identify strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.  For more information, please visit www.canopyrivers.com.

Forward-Looking Statements

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the completion of the transactions discussed herein and the anticipated benefits thereof; the shipment of pharmaceutical-grade cannabis products into German; and other expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; the inability of the parties to satisfy the conditions to closing set out in the definitive documentation in a timely manner or at all; competition for global, regulated cannabis opportunities; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ final short form prospectus dated February 21, 2019, filed with Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

$TGOD $TGODF Settlement with Hamilton City Council Approved

HAMILTON, ON, May 3, 2019 – The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF) is pleased to confirm that the Hamilton City Council and the Company have finalized and signed a settlement offer, and that the Local Planning Appeal Tribunal approved the settlement at a meeting on May 2, 2019. The facilities in Ancaster, Ontario will be capable of growing 17,500 kgs of premium certified organic cannabis annually.

“This completes this chapter of our journey,” said Brian Athaide, CEO of TGOD. “We look forward to growing and producing high-quality, certified organic cannabis right here in our home town. We are committed to the City and look forward to working with our neighbours, local businesses and the community.”

About The Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The Company grows high quality, certified organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about future facility construction, statements about future jobs to be offered by the Company, statements about production timing, efficiencies, capacities and ramp-up, statements about future production, statements about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

$LXRP Execs Sign Three-Year Contract Extensions

• LXRP CEO Chris Bunka and President John Docherty have agreed to new, three-year contracts
• The new contract agreements are designed to provide management security with continuity of key officers
• The company recently canceled 1,140,000 stock options after negotiations with optionees

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has successfully negotiated new three-year compensation contracts with key officers Chris Bunka, CEO, and John Docherty, president. The agreements offer LXRP and its shareholders the security of pursuing corporate growth within a seamless transition by providing management continuity. The renewal agreements are retroactive to January 1, 2019 (http://nnw.fm/J20Ew).

The agreements offer both officers compensation and bonuses based on meeting certain performance criteria established by the LXRP board. The agreements also offer a one-time bonus based on consideration for the…

Read more »

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://nnw.fm/LXRP

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$GNPX Positive Preclinical Data in Lung Cancer Treatment Study

$TGODF $TGOD and Epican, Second Retail Licence & Retail Dispensary in Jamaica

MONTEGO BAY, Jamaica, May 1, 2019  – The Green Organic Dutchman Holdings Ltd. (“TGOD” or the “Company”) (TSX: TGOD) (US: TGODF) is pleased to announce, in conjunction with Epican Medicinals (“Epican”), the opening of its second legal cannabis retail store in Jamaica. Located on Montego Bay’s “Hip Strip”, the flagship location will open for business on May 4, 2019.

Montego Bay is a popular tourist destination and Jamaica’s second largest city. It is also a major port of call for cruise ships, a destination for duty free shopping and home to the country’s largest airport. The Montego Bay flagship dispensary, located on the main tourist shopping strip, is the second Epican dispensary to open, after Epican’s Herb House in Kingston which opened in June 2018. Epican is the first fully integrated company to have obtained a second retail licence from Jamaica’s Cannabis Licensing Authority (CLA).

Epican plans to open three additional Herb Houses on the island. In combination with online ordering, these locations will serve the medical needs of Jamaica’s three million residents and over three and a half million annual visitors.

“We are proud of what the team in Jamaica has accomplished. Epican’s Montego Bay store is a bright and well-designed space ideally located to serve local and visiting patients with Epican’s locally produced premium organic cannabis,” commented Brian Athaide, CEO of TGOD. “Our Kingston location witnessed increasing sales volumes; setting the stage for the grand opening of an Epican Herb House in Jamaica’s largest tourist hub. It is an important milestone toward further expansion for Epican and TGOD in Jamaica.”

Jamaica is recognized as a premier destination for cannabis, and Epican has deep roots in the country. The founders, the McKenzie brothers, have been at the forefront of the nation’s burgeoning medical cannabis industry, including advocacy for the responsible development of the sector. Epican was awarded the country’s historic first cultivation licence.

“Today is yet another celebration for Epican and TGOD,” stated Karibe McKenzie, CEO of Epican. “We have worked tirelessly to provide a fully-integrated solution delivering high-quality medical cannabis to Jamaicans and tourists alike, and the response in Kingston has been overwhelming. We can’t wait to make our mark in Montego Bay.”

TGOD owns 49.18% of Epican, and the joint organization is partnering to construct a GMP compliant facility in Jamaica. Upon receiving the licence for this site expansion, Epican will cultivate premium strains for the Jamaican and international market.

On Behalf of the Board of Directors,

The Green Organic Dutchman Holdings Ltd.

ABOUT THE GREEN ORGANIC DUTCHMAN HOLDINGS LTD.

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly owned subsidiary HemPoland distributes premium hemp CBD oil in the EU. The Company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to,, statements about future dispensary openings in Montego Bay and throughout Jamaica, statements about future facility construction, statements about the achievement of certain certifications in connection with its facilities, statements about the receipt of any regulatory permits or licences,, statements about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

$NUGS Entering CBD Retail Space with FLORAH Lifestyle Boutiques

$PBIO Announces CEO Succession Plan

$VVCIF Posts Q4 and 2018 Annual Financial, Operational Results

$TCAN Applies For Mfg., Distribution & Transportation Licenses at Adelanto Facility

Vancouver, British Columbia–(April 30, 2019) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) applied for a permanent manufacturing, distribution and a transportation license this week with the city of Adelanto, CA.

“Our immediate focus is to be able to have our city and state licenses in place in Adelanto as soon as possible. Subsequent to the GoodFellas acquisition we will be able to prepare and package the Daily Cannabis Brand pre-rolls at the facility and then deliver the products to the dispensaries without the need to bring in a third party,” stated Jim Pakulis, CEO of TransCanna.

“And as previously stated, the Daily Cannabis Brand has trended in percentage of sales increase since it began selling in the summer of 2018, and our goal is to provide not only the Daily Cannabis Brand with the necessary resources to continue and grow, but to use the Adelanto facility as the first TransCanna satellite distribution network facility throughout the state in an effort to provide reliability, consistency and quality to the dispensaries, and just as importantly scale TransCanna’s ecosystem as expeditiously as possible.”

The Company will provide an update later in the week as it relates to the licensing process for its 196,000 square foot facility in Modesto, CA.

For further information, please visit the Company’s website at www.transcanna.com.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a Canadian-based company focused on providing integrated branding, transportation and distribution services, through its wholly-owned California subsidiaries, to a range of industries including the cannabis marketplace.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at info@transcanna.com.

Media Contact
TransCanna@talkshopmedia.com
604-738-2220

On behalf of the Board of Directors

James Pakulis
Chief Executive Officer

Telephone: (604) 609-6199

The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

$TGODF $TGOD Extraction Services Provider Obtains Organic Certification

$NETE Aptito Collaborates with HP Inc. for SMB Market

Aptito Becomes an HP Channel Partner for Sales and Support of HP POS Solutions

MIAMI, FL, April 30, 2019 — via NEWMEDIAWIRE – Net Element, Inc. (NASDAQ: NETE)(“Net Element” or the “Company”), a global technology and value-added solutions group that supports electronic payments acceptance in a multi-channel environment including point-of-sale (“POS”), today announces that its Aptito subsidiary has entered into a channel partner agreement with HP Inc. for sales and support of its line of Android-based POS devices.

The Electronic Transaction Association (“ETA”) Payments Trends to Watch report predicts that US merchants will spend nearly $2 billion on frictionless payment solutions such as technology-enabled integrated POS solutions (IPOS) in 2019, underscoring the value that advanced payments solutions provide to merchants and payment service providers. Net Element is poised to benefit as these merchants upgrade their traditional POS systems to user friendly IPOS solutions that inspire customer loyalty and maximize revenue potential.

According to the U.S. Small Business Administration there is an addressable market of an estimated 600,000 small and mid-sized businesses (SMBs) in the United States. Aptito’s goal is to provide its restaurant management software-as-a-service (SaaS) alongside HP’s POS solutions to offer SMBs cutting-edge technology and competitively priced value-added services backed by HP’s global sales and support. In addition, HP’s Android-based IPOS solutions come with a full suite of retail peripherals and accessories that can be used as tools for assisted selling and mobile transactions.

“We are excited to work with HP to deliver our SaaS in their IPOS solutions to our existing and new merchants worldwide,” commented Andrey Krotov, President of Aptito. “Aptito is currently deployed in 16 countries and growing, HP’s global sales and support provide a springboard for continued expansion.”

About Net Element

Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. In the U.S., the Company aims to grow transactional revenue by innovating SME productivity services using various technology solutions and Aptito, our cloud-based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 and 2018 Technology Fast 500™. In 2017 we were recognized by South Florida Business Journal as one of 2016’s fastest-growing technology companies. Further information is available at www.NetElement.com.

Forward-Looking Statements

Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict.  Examples of such risks and uncertainties include whether the Company will benefit from any merchants who upgrade their traditional POS systems, whether Aptito will be successful in its restaurant management SaaS initiatives and whether the relationship will result in continued expansion for the Company. Further examples of such risks and uncertainties include but are not limited to (i) Net Element’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element’s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element’s ability to successfully expand in existing markets and enter new markets; (iv) Net Element’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element’s business; (viii) changes in government licensing and regulation that may adversely affect Net Element’s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element’s business; (x) Net Element’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; and (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Contact:
Net Element, Inc.
+1 (786) 923-0502
www.NetElement.com
Media@NetElement.com

Corporate Communications Contact:
NetworkWire (NNW) 
New York, New York 
www.NetworkNewsWire.com
212.418.1217 Office 
Editor@NetworkWire.com

$NUGS Realizes Key Achievements – NetworkNewsBreaks

$LXRP Innovative Technology Improves Delivery of Nicotine, Cannabinoids

$GGBXF Announces Expiration of Former $APHA Acquisiton Offer

$VVCIF $VIVO Group Plans 2020 Ballot Measure to Legalize Recreational – 420 with CNW

$TGOD $TGODF European Acquisition HemPoland Receives Organic Certification

TORONTO, April 26, 2019 – The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX: TGOD) (US: TGODF) is pleased to announce that its wholly owned subsidiary, HemPoland, has received organic certification from EKOGWARANCJA PTRE. This organic certification is provided by the Polish Center for Accreditation on authority from the Minister of Agriculture and Rural Development. HemPoland’s facilities, production processes and product offerings are now certified organic.

TGOD’s extraction and formulation of premium high-quality hemp oils from certified organic raw materials within Poland, sets the foundation for novel and proprietary products to be offered throughout Europe and global markets with official PL-EKO-01 EU certificates. TGOD’s newly certified facility expands its global reach for certified organic production.

“We are incredibly excited that HemPoland’s facilities, production and processes have received organic certification within Europe,” stated Brian Athaide, CEO of TGOD. “This is a major point of differentiation that offers consumers a premium experience. We are proud to continue to deliver and execute on our global organic strategy.”

EKOGWARANCJA PTRE is the largest certification body supported by the Polish Ministry of Agriculture and Rural Development, certifying operators whose goods are being produced in accordance with council regulations.

On Behalf of the Board of Directors,
The Green Organic Dutchman Holdings Ltd.

About The Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) is a publicly traded, premium global organic cannabis company, with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. The Company grows high quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 sq. ft. of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark.

TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively.

For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward looking statements in this release includes, but is not limited to, statements about future research, development and innovation by the Company, statements about delivery of product, statements about future production and supply, statements about hemp production and product offerings, statements about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.

$PBIO Record Q4 FY18 Financial Results, Provides Business Update

• Q4 2018 Total Revenue Increases 37% over Q4 2017, Setting New Record Quarterly High;
• FY 2018 Total Revenue Increases 10% over FY 2017, Setting New Record Annual High;
• Initial Revenue Reported from New BioPharma Services and UST Businesses;
• Balance Sheet Improves with Significant Conversion of Debt to Equity.
• Investor Conference Call Scheduled for Thursday, April 25, 2019 at 4:30 PM EDT

SOUTH EASTON, MA / April 25, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and other industries, today announced financial results for the fourth quarter and fiscal year ended December 31, 2018, provided a business update, and offered limited guidance for FY2019.

Financial Results: Q4 2018 vs. Q4 2017

Total revenue for Q4 2018 was $686,558 compared to $502,708 for the same period in 2017, a 37% increase. This increase was primarily due to our double-digit growth in products and services and in grant revenues.

Products and services revenue was $535,860 for the fourth quarter of 2018 compared to $455,767 for the same quarter of 2017, an 18% increase. Sales of instruments increased to $388,356 in Q4 2018 compared to $317,498 in Q4 2017, an increase of 22%. Sales of consumables were $52,935 for 2018 fourth quarter compared to $60,108 for the same period in 2017, a 12% decrease. Grant revenue in Q4 2018 was $150,698 compared to $46,941 in Q4 2016 an increase of 321%.

Operating loss for Q4 2018 was $1,514,730 compared to $1,318,384 for the same period in 2017. This increase in operating loss was primarily due to increases in general and administrative expense.

Loss per common share – basic and diluted – was $(2.93) for Q4 2018 compared to $(2.37) for the same period in 2017.

Financial Results: FY2018 vs. FY2017

Total revenue for FY2018 was $2,457,871 compared to $2,240,498 for FY2017, a 10% increase. This increase was primarily due to our growth in products and services and in grant revenues.

Products and services revenue was $2,200,539 for the year ended December 31, 2018 compared with $2,065,891 for the year ended December 31, 2017, a 7% increase. Sales of instruments decreased to $1,418,731 for FY2018 compared to $1,459,326 for FY2017, a decrease of 3%. Sales of consumables were $235,132 for the year ended December 31, 2018 compared to $260,331 for the same period in 2017, a decrease of $25,199 or 10%. Grant revenue for fiscal year 2018 was $257,332 compared to $174,607 for the 2017 fiscal year, an increase of $82,725 or 48%.

Operating loss for FY2018 was $4,477,083 compared to $4,647,048 for FY2017. This decrease was primarily due to increases in total revenue.

Loss per common share – basic and diluted – was $(15.33) for FY2018 and $(9.62) for the 2017 fiscal year.

Operational & Technical Highlights: FY2018

• Bradford A. Young, Ph.D., MBA Joins PBI as Senior VP and Chief Commercial Officer in November 2018.

• We Converted $13.6 Million of Debt into Equity, Significantly Reducing Total Liabilities.

• A Major Cancer Research Center Reported that Our Patented Pressure Cycling Technology (“PCT”) Platform Could Play Major Role in Improving Cancer Diagnosis and Treatment.

• PBI and ISS, Inc. Announced Two-Year Worldwide Co-Marketing and Distribution Agreement.

• We were Awarded a Key U.S. Patent for Novel High-Pressure Flow-Through Microfluidic Sample Prep Device.

• Our Ultra High-Pressure Instruments, Processing Methods, and Platform Technologies were Prominently Featured at a Leading, Worldwide Food Science Meeting.

• We Announced the First Contract Utilizing our Recently Acquired, Patented Protein Refolding and Disaggregation Platform Technology from our December 2017 Purchase of All Assets of BaroFold, Inc.

• We Accelerated the Development of our Novel Ultra Shear Technology™ (“UST™”) Platform to Pursue Commercialization into Major New Markets, Including Food & Beverages, Nutraceuticals, and Cosmetics.

• Our Patented UST Platform was Featured as a Potential Breakthrough Processing Method for Higher Quality, Longer Lasting Liquid Foods and Beverages not requiring Refrigeration or Chemical Additives, such as Shelf Stable Milk and Other Dairy Products.

• We Announced a Strategic Collaboration with Ohio State’s College of Food, Agriculture, and Environmental Sciences, and were Awarded $318,000 from a USDA Grant to Build the First Prototype UST Instrument.

• We Achieved Two Major Milestones in the Development of our Proprietary UST Technology Platform, Including the Development of a UST-based Process to Make Nanoemulsions of CBD Plant Oil from Hemp.

Mr. Richard T. Schumacher, President and CEO of PBI, said: “This past year was filled with multiple significant financial, operational and technological accomplishments. Key among these was the hiring of Dr. Brad Young as PBI’s Chief Commercial Officer. In this leadership role, Dr. Young will be responsible for assessing multiple major new and divergent market opportunities, and for optimizing the commercialization priorities and strategy for PBI. In addition to this essential role in strategic planning, Dr. Young will also drive the execution of critical partnering and commercialization programs to build customer adoption and accelerate growth.”

Dr. Bradford A. Young, Chief Commercial Officer of PBI, commented: “We are pleased with the overall performance of the Company in 2018, especially in Q4 when total revenue reached a record, all-time high for quarterly revenue. In addition to recording significantly increased sales of our core, PCT platform in 2018, we also recorded the first revenue from our newly launched BioPharma Services business. Our BioPharma Services business helps us not only monetize the BaroFold assets we acquired in December 2017 for improved manufacturing of protein therapeutics, but also supports sales of our Barocycler PCT platform. In fact, we use the Barocycler 2320 EXTREME to perform our BioPharma Services and saw increased demand for our Barocycler 2320 EXTREME in 2018 for quality control applications used during the manufacturing of protein therapeutics.”

Dr. Young continued: “It’s clear that our PCT and BaroFold platform technologies can help companies produce new and improved therapeutic products, a market that is expected to reach $240 billion dollars by 2023 (ResearchAndMarkets.com, 2018). In addition, the new, cutting-edge Ultra Shear Technology (UST) platform we are developing for the production of high-quality nanoemulsion mixtures of oil & water can provide an enhanced way to deliver therapeutics or drugs. Thus, our UST platform has the potential to provide a superior method to develop and deliver drug formulations with improved bio-absorption and faster uptake. We look forward to building on the great progress we’ve made in 2018 and growing the adoption of our life sciences platform technologies for research, development and manufacturing applications in 2019 and beyond.”

Earnings Call

The Company will hold an Earnings Conference Call at 4:30 PM EDT on Thursday, April 25, 2019. To attend this teleconference via telephone, Dial-in: (844) 602-0380 (North America), (862) 298-0970 (International). Verbal Passcode: PBIO Fourth Quarter and Fiscal Year 2018 Financial Call. Replay Number (877) 481-4010; (919) 882-2331 (International). Replay Passcode: 47337. Teleconference Replay Available for 30 days.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired protein disaggregation and refolding technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology™ (“UST™”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company’s financial results for the year ended December 31, 2018 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:

Richard T. Schumacher, President and CEO
(508) 230-1828 (T)
Bradford A. Young, Ph.D., MBA, SVP and CCO
(508) 230-1829 (F)

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS

$VVCIF Municipal Approval for B.C. Facility Expansion

$LXRP Expands Advisory Board

KELOWNA, BC / April 25, 2019 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, is pleased to announce new appointments to its Scientific Advisory Board, each of whom will contribute advice and recommendations and support related to the Company’s scientific research and product development. Lexaria is honored to have the opportunity of working with each of them.

Dr. Dwayne Godwin is Dean of the Graduate School and Professor in the Departments of Neurobiology and Anatomy and the Institute for Regenerative Medicine at Wake Forest University. He is a neuroscientist with extensive experience in studies of synaptic pharmacology of the brain and translational interests in the physiological basis and neuroimaging of brain injury, alcohol abuse, epilepsy and seizure, Alzheimer’s and PTSD. Dr. Godwin also has experience creating, developing and administering programs at the interface between science, technology, and business, and experience consulting with the pharmaceutical industry on preclinical drug development. He earned his PhD in Behavioural Neuroscience from the University of Alabama, and completed a Postdoctoral Fellowship at the State University of New York – Stony Brook.

Dr. Terry D. Blumenthal is Professor, Psychology and Neuroscience, at Wake Forest University, and is past president of the Society for Psychophysiological Research. His research interests include psychophysiology, research design and methodology, PTSD, information processing, schizophrenia, and developmental neuroscience. Dr. Blumenthal has over 115 publications and has delivered over 200 formal presentations at prestigious events held around the world. He earned both his PhD and MS degrees in Psychology from the University of Florida, and his BSc from the University of Alberta.

Dr. Matthew Fraser is Associate Professor and Director of Basic Science Research in the Department of Surgery, Division of Urology, at Duke University Medical Center. Dr. Fraser has extensive experience in urological and gastrointestinal neuroscience preclinical research, development of research models and methods, experimental design, and early clinical development in both academic and industry settings. He earned his PhD in Physiology/Neuroscience from the University of Pittsburgh School of Medicine.

Dr. Carla Lema Tome is an industry consultant an Adjunct Assistant Professor of Neurobiology and Anatomy at Wake Forest University School of Medicine. She is widely published on topics including but not limited to cellular and molecular neuroscience, inflammation, neurodegeneration, and cancer biology. She has extensive experience in global medical and commercial strategy consulting with emphasis on integrated clinical development, asset and portfolio strategy, launch planning payer research and payer value communications. Her work supporting bioscience projects with high market potential includes the development of forecast and valuation models, conducting strategic analyses of the competitive and market access environment, and developing integrated plans and innovative strategies to maximize asset value. Dr. Lema Tome earned her PhD in Neurobiology and Anatomy and her MBA from Wake Forest University. She also earned an MS in Biological Sciences, Marine Biology, from the Florida Institute of Technology.

“Lexaria Bioscience Corp. is very pleased to welcome these accomplished experts to our Advisory Board, who can provide critical scientific guidance to Lexaria’s ongoing and future R&D programs,” said Chris Bunka, Chief Executive Officer of Lexaria Bioscience Corp. “Lexaria is building towards becoming one of the world’s leaders in drug delivery technology and our most recent Advisors can assist in achieving that goal.”

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter https://twitter.com/lexariacorp and on Facebook https://www.facebook.com/lexariabioscience/

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(250)765-6424 Ext 202

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. Scientific R&D is often unpredictable and unanticipated results could emerge from any study and have a material impact. There is no assurance that any planned corporate activity, scientific study, R&D, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). TurboCBD^TM, DehydraTECH^TM technology and ViPova^TM products are not intended to diagnose, treat, cure or prevent any disease.

$NUGS Plants 20,000 at New 6-Acre Licensed Cannabis Site

LOS ANGELES, April 25, 2019  — via NetworkWire — Los Angeles based Cannabis Strategic Ventures Inc. (OTC: NUGS) today announces a major addition to its corporate portfolio through the launch of a six-acre cannabis cultivation site expected to produce a minimum of 30,000 pounds of cannabis per harvest, with an anticipation of four to five harvests per year.

The site, which has been named NUGS Farm North, is located in Northern California. NUGS Farm North is primarily a cultivation operation but will also host manufacturing and distribution business units for Cannabis Strategic Ventures. In total, the site holds 24 cultivation, manufacturing and distribution licenses issued by the Bureau of Cannabis Control in the State of California. NUGS Farm North is expected to operate at maximum capacity by late summer of 2019.

“This is a significant event for Cannabis Strategic and its investors,” commented Simon Yu, CEO Cannabis Strategic Ventures. “NUGS Farm North has planted over 20,000 marijuana clones this week and will plant 10,000 more next week. Beyond the initiation of this first phase of NUGS farm North, we anticipate further expansion towards maximum capacity, which will increase top line revenue.”

Cannabis industry figures show that cannabis plants yield more than one pound of cannabis per harvest. In California, the wholesale price for cannabis opened 2018 at $1,455 per pound and closed the year at $1,196 per pound, averaging $1,197 per pound for the year, according to Cannabis Benchmarks.

The Company has retained a highly skilled team to operate NUGS Farm North consisting of experts with over a dozen years of full lifecycle cannabis operations, as well as research scientists with vast scientific, medical and laboratory backgrounds unique to cannabis operations.

“NUGS Farm North is in a prime location. We have assembled a great team to operate the site and to market and distribute its outputs.  We have already begun cultivation and believe the marketplace is primed for the type of premium cannabis flower we are cultivating.  We look forward to a successful operation at our flagship cultivation site,” added Yu.

About Cannabis Strategic Ventures
Cannabis Strategic Ventures is a Los Angeles-based firm that incubates, develops and partners with category leaders within the cannabis sector. The Firm’s NUGS brand experience provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands. The company recently completed a name and symbol change from Cascade Energy, Inc. Cannabis Strategic Ventures is publicly traded on the U.S. Over the Counter Market with the stock symbol NUGS. For more information, visit www.CannabisStrategic.com

FORWARD-LOOKING STATEMENTS: This release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management’s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “would,” “could,” “will” and other words of similar meaning in connection with a discussion of future operating or financial performance.

Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance.

Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company’s actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others such as, but not limited to economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. Any forward-looking information provided in this release should be considered with these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.

Contact:
Arlene Guzman
1-310-359-6860 Office
IR@CannabisStrategic.com
www.CannabisStrategic.com

Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com

$YGYI Subsidiary Secures Notable CBD Supply Contract

$LXRP Beverage License Agreement with California Cannabis Company

Kelowna, British Columbia / April 24, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria CanPharm ULC, to provide Lexaria’s patented DehydraTECHTM technology to a private California-based cannabis company for its utilization in certain cannabis-based beverages to be produced and sold in the states of California and Nevada.

Financial terms of the agreement are not being disclosed. The DehydraTECH-enabled beverages are protected under Lexaria’s many existing US-granted patents and may include any combination of ready-to-drink beverages such as non-alcoholic beers, wines and spirits; cold or hot coffee or teas, sports drinks and much more.

Lexaria has developed methods of combining nano-emulsion technology with its proprietary DehydraTECH processes to create beverages with market-leading aesthetic and performance characteristics. Lexaria is currently experiencing unprecedented demand in several North American markets for use of its technology for beverage applications.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs),nicotine and other molecules.

www.lexariabioscience.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.

Alex Blanchard, Communications Manager

(250)765-6424 Ext 202

Or

NetworkNewsWire (NNW)

www.NetworkNewsWire.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. Scientific R&D is often unpredictable and unanticipated results could emerge from any study and have a material impact. There is no assurance that any planned corporate activity, scientific study, R&D, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). TurboCBDTM, DehydraTECHTM technology and ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.

$PBIO to Discuss Q4 FY18 Financials, Business Update, Apr 25

Conference Call Scheduled for Thursday, April 25^th at 4:30pm ET

SOUTH EASTON, MA / April 24, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2018 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company’s website approximately one day after the teleconference).

The teleconference will include a Company presentation followed by a question & answer period.

Date: Thursday, April 25, 2019 Time: 4:30 PM Eastern Time (ET)

To attend this teleconference, live by telephone:

Dial-in: (844) 602-0380 (North America); (862) 298-0970 (International)

Verbal Passcode (for the operator): PBI Fourth Quarter and FY 2018 Financial Call & Business Update

For those unable to participate in the live teleconference, a replay will be available beginning Friday, April 26, 2019. The replay will be accessible via telephone and the Company’s website for 30 days.

Replay Number: (877) 481-4010 (North America); (919) 882-2331 (Int’l); Replay Passcode: 47337

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

For more information about PBI and this press release, please click on the following link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:

Richard T. Schumacher, President & CEO (T) 508-230-1828
Bradford A. Young, Ph.D., MBA, SVP & CCO (F) 508-230-1829

$NETE Noteworthy Revenue Growth Driven by NA Transaction Solutions

$TCAN Completes Acquisition of Large California Site

• TransCanna Holdings’ purchase of a 5.5-acre site in Northern California with a 196,000-square-foot facility onsite is expected to set the stage for the company’s self-contained ecosystem to create or acquire 15 premium brands by controlling all aspects of production, distribution and sales
• Cannabis sales in California are expected to reach $5.1 billion this year and climb to $7.7 billion by 2022
• TransCanna’s site purchase advances plans for an additional 600,000-square-foot facility for biomass growth
• A successful, oversubscribed private placement raised gross proceeds of C$16 million to help fund plans for the site

Cannabis branding and distribution company TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) has finalized the acquisition of “arguably the largest vertically integrated cannabis centric” multi‐purpose facility in California, setting the stage for edification of a self-contained cannabis hub operation that includes integrated divisions for transportation and distribution, cultivation and nursery, lab extraction, manufacturing and packaging.

The three-story, 196,000-square-foot facility is part of a larger 5.5-acre property purchase that the company envisions as green space, where up to 600,000 square feet of new …

Read more »

NOTE TO INVESTORS: The latest news and updates relating to TCAN are available in the company’s newsroom at http://nnw.fm/TCAN

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

$TCAN Will Acquire Daily Cannabis Goods Brand, GoodFellas Acquisition

Vancouver, British Columbia–(April 23, 2019) – TransCanna Holdings Inc. (CSE: TCAN) (XETR: TH8) (“TransCanna” or the “Company”) announces that the acquisition of GoodFellas will result in acquiring an additional existing brand called Daily Cannabis Goods (“Daily”). The Daily brand consists of three quality half gram pre-rolls which are attractively packaged and priced.

“The Daily brand is a perfect fit for TransCanna,” Stated Jim Pakulis, CEO of TransCanna. “The start-up costs were nominal, it has SKU velocity now that it’s selling in over thirty dispensaries, and it’s constantly beating the competition due to consumer demand.”

“The Daily brand has seen a steady consistent increase in sales since it commenced in August 2018. The first month shipments of units exceeded 2,100 and by December the number of units shipped for the month exceed 10,000. We anticipate closing the acquisition of GoodFellas by May 20^th, and then we’ll budget accordingly in order to work on increasing units sold.”

Subsequent to the acquisition, TransCanna anticipates expanding the Daily line to include three additional SKU’s.

For further information, please visit the Company’s website at www.transcanna.com.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a Canadian-based company focused on providing integrated branding, transportation and distribution services, through its wholly-owned California subsidiaries, to a range of industries including the cannabis marketplace.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at info@transcanna.com.

Media Contact
TransCanna@talkshopmedia.com
604-738-2220

On behalf of the Board of Directors

James Pakulis
Chief Executive Officer

Telephone: (604) 609-6199

The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

$TGOD $TGODF on the Move, Big Deal Behind the Oil Sales License

In a press release earlier today, The Green Organic Dutchman (TSX:TGOD) (OTCQX:TGODF) announced that it has received its oil sales license from Health Canada. The news has spurred on TGOD stock, which, as a result, is up roughly 7% and trading at $4.18 CAD on the TSX.

TGOD Stock: Oil Sales License

The news comes a short time after the company received its oils production license earlier this month.

Upon that news, TGOD installed a “state-of-the-art supercritical CO2 extraction system, capable of processing ultra-pure, environmentally friendly, organic cannabis oils.”

This focus on high-quality certified-organic cannabis is exactly what TGOD is famed for. Its aim to create ultra-premium cannabis products is possible because of the company’s extraction process. This is a unique protocol that results in a cannabis oil “as close to the original plant composition” as possible.

Now, with the sales license in hand, TGOD will embark on the global sale of this high-quality cannabis oil, much to the excitement of TGOD stock investors.

In the press release, TGOD CEO Brian Athaide said the following:

“We are pleased to offer TGOD’s medical patients access to new premium certified organic cannabis oils […] In addition, this step will assist TGOD in transforming our premium quality organic raw material into a variety of higher-margin cannabis products which is core to our business plan, providing us with the opportunity to bring to market innovative and novel products, including beverages and edibles, once regulations permit. Cannabis 2.0 is rapidly approaching, and we will be ready.”

TGOD Stock: Grower’s Circle

In March, The Green Organic Dutchman announced that the sale of its cannabis flower had started. A select group of medical patients called the Growers’ Circle, were given early access to the company’s first-certified organic flower. This initial rollout was a limited offering used to help TGOD perfect distribution and gauge response ahead of the company’s full-scale rollout, which will now include cannabis oils.

Initial feedback from the Grower’s Circle has, according to the company, been extremely positive.

Now, TGOD’s Unite Organic Cannabis Oil will begin shipping later this month.

$GGBXF Canadian and U.S. Cannabis Firms To Enter Joint Cultivation Agreements

Palm Beach FL – April 23, 2019 –  Canada was the first North American country to legalize cannabis and that gave it an advantage, but it is the U.S. that is projected to have the larger number of consumers in 2019. U.S. companies will need the expertise of the Canadian growers and Canadian growers will need to work with U.S. companies to enter this larger market. Mergers and marriages should abound in 2019. Bloomberg, has said that recently, most U.S.-focused cannabis companies saw higher gross margins than their Canadian counterparts, and as a result, many of Canadian companies are beginning to establish operations in the U.S.   Conversely, even with the U.S. having vast growth opportunities, U.S. cannabis companies are still expanding their operations in Canada. According to Arcview Market Research and BDS Analytics, Canada reported legal cannabis sales in the range of USD $755 Million to USD $1.6 Billion. So in the near future, the U.S. and Canada combined, are projected to be the biggest market drivers for the global cannabis industry.      Active companies in the cannabis industry includes:  CROP INFRASTRUCTURE CORP. (CSE:CROP) (OTC:CRXPF), CV Sciences, Inc. (OTC: CVSI), Green Growth Brands Inc. (CSE: GGB) (OTC: GGBXF), Newstrike Brands Ltd. (TSX-V: HIP) (OTC: NWKRF), The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTC: TGODF).

A recent Forbes article had the following headline: “2019 Explosion Of Cannabis Mergers And Acquisitions Predicted”. The article continued: “Most of the businesses growing, processing and selling cannabis across the United States are small independently-held entities. That may change in 2019 which looks like a big year for industry mergers, acquisitions and expansion. The cannabis industry still has a mom and pop feel but that could change rapidly. A few have made that leap and are establishing footholds in states around the country. In 2018, some of the multi-state operators acquired additional licensed operators in new locations. By the end of the year, “We were seeing larger companies merge with one another,” said  (an industry insider). As the industry continues to grow and mature, he expects to see more of this consolidation in 2019.”

CROP INFRASTRUCTURE CORP. (CSE:CROP) (OTCPK:CRXPF) (Frankfurt: 2FR) BREAKING NEWS:  CROP announced today that it has completed the construction of its 57,600 square foot nursery in Nye County, Nevada.   It has been equipped with trays and LED lighting specially designed to enhance the growth of plant starts for the 2019 CBD farms licenced on the company’s various properties in the state. This was a key project in order to maximize yield, reduce farming risk and costs for the 2019 planting season.

CROP continues to gauge interest and review potential off take relationships for the 2019 season for its CBD products.  The global medical cannabis market value is expected to reach a value of US$ 45.4 Billion by 2024, with a CAGR of 22.9% during 2019-2024, according to IMARC research. The firm’s estimate for last year was that it would to reach US$ 13.4 Billion.

CROP CEO, Michael Yorke, stated: “The CROP family of companies and subsidiaries continues to build strategic infrastructure in key states where we are present. These are one time builds that will streamline harvests, reduce risks and costs as well as maximize yields for many years to come.

“We are very proud of our team members for putting in the extra hours to ensure the season ahead is as successful and profitable as can be. We are encouraged by the number of interested parties in the products we are producing and will look to secure long term reliable relationships to the benefit of stakeholders and the company’s farming, marketing and construction divisions.”    Read this full announcement and more news for CROP Infrastructure at:   https://www.financialnewsmedia.com/news-crop/

Additional cannabis industry related developments from around the markets:

CV Sciences, Inc. (OTCQB: CVSI) a preeminent supplier and manufacturer of hemp CBD products, recently announced further expansion of its industry-dominating brand, PlusCBD Oil™. As of March 31, 2019, PlusCBD Oil™ branded products are available in 3,308 retail stores, up 48% from 2,238 retail stores as of December 31, 2018.

The expansion includes broadening distribution of its best-selling topical, PlusCBD Oil™ Extra Strength Balm, into the Food, Drug and Mass (FDM) channel, including programs with leading national retailers.

Green Growth Brands Inc. (CSE: GGB.CN) (OTCQB: GGBXF) a cannabis and CBD retailer specializing in creating remarkable consumer experiences, recently  announced the launch of CAMP™, a proprietary cannabis brand.

CAMP™ is a brand born from the idea of connecting with nature, connecting with others and connecting with yourself.  A strategic component of GGB’s owned and operated portfolio of brands, CAMP™ will be a destination for the cannabis community; a place to find premium products that support and enhance an active lifestyle. Beginning with proprietary TCH and CBD products, GGB expects to also launch the first CAMP dispensary in this year.

Newstrike Brands Ltd. (TSX-V: HIP.V) (OTCPK: NWKRF) recently announced that it is making a US$5 million investment in Green Tank Technologies (“Green Tank”), one of North America’s premiere manufacturers of cannabis vape hardware and technology. The investment by Newstrike strengthens the existing partnership between Newstrike’s wholly-owned subsidiary, Up Cannabis, and Green Tank, as both companies prepare for the legalization of cannabis oil vaping.

“In anticipation of revised cannabis regulations coming into force in late 2019, we are gearing up for the commercial launch of our full line of cannabis vape products. Our strategic investment in Green Tank puts us in a strong position to become a preferred supplier of end-to-end vape solutions to the adult use recreational market,” said Mark E. Burton , Chief Strategy Officer, Newstrike Brands.

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD.TO) (OTCQX: TGODF) recently announced it has received its oil sales license from Health Canada pursuant to the Cannabis Act for its Hamilton, Ontario facility.

The Company received its oils production license in April of 2018 and subsequently installed a state-of-the-art supercritical CO2 extraction system, capable of processing ultra-pure, environmentally friendly, organic cannabis oils. The process is free of toxic solvents and does not require any winterization protocol. The result of this specialized extraction process is a precisely concentrated, aromatic golden-brown oil that is as close to the original plant composition as can be achieved. TGOD’s premium cannabis products, including its cannabis oils, are certified organic by ProCert and its innovative growing process is certified organic by both ProCert and Ecocert, producing a clean, high-quality end product.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com (FNM) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM has been compensated forty nine hundred dollars for news coverage of the current press release issued above by CROP Infrastructure Corp. by a non affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.